Characterization of response to atezolizumab + bevacizumab versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trial

BACKGROUND: IMbrave150 is a phase III trial that assessed atezolizumab + bevacizumab (ATEZO/BEV) versus sorafenib (SOR) in patients with unresectable hepatocellular carcinoma (HCC) and demonstrated a significant improvement in clinical outcomes. Exploratory analyses characterized objective response...

Descripción completa

Detalles Bibliográficos
Autores principales: Salem, Riad, Li, Daneng, Sommer, Nicolas, Hernandez, Sairy, Verret, Wendy, Ding, Beiying, Lencioni, Riccardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366100/
https://www.ncbi.nlm.nih.gov/pubmed/34189869
http://dx.doi.org/10.1002/cam4.4090

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366100/
https://www.ncbi.nlm.nih.gov/pubmed/34189869
http://dx.doi.org/10.1002/cam4.4090

Ejemplares similares